

Don R Husereau

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4510174/don-r-husereau-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

80
papers

4,700
citations

23
h-index

68
g-index

98
ext. papers

6,029
ext. citations

3
avg, IF

5.11
L-index

#	Paper	IF	Citations
80	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>BMC Public Health</i> , 2022 , 22, 179	4.1	2
79	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022 , 1-10	1.9	
78	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>BMC Health Services Research</i> , 2022 , 22, 114	2.9	2
77	Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>International Journal of Technology Assessment in Health Care</i> , 2022 , 38, e13	1.8	5
76	Estándares Consolidados de Reporte de Evaluaciones Económicas Sanitarias: adaptaci3n al espa3ol de la lista de comprobaci3n CHEERS 2022.. <i>Value in Health Regional Issues</i> , 2022 , 27, 110-114	1.6	0
75	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. <i>Value in Health</i> , 2022 , 25, 3-9	3.3	14
74	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>MDM Policy and Practice</i> , 2022 , 7, 23814683211061097	1.5	0
73	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. <i>Health Policy OPEN</i> , 2022 , 3, 100063	1.9	2
72	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>BMC Medicine</i> , 2022 , 20, 23	11.4	6
71	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. <i>Applied Health Economics and Health Policy</i> , 2022 , 20, 213	3.4	1
70	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>European Journal of Health Economics</i> , 2022 , 1	3.6	1
69	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022 , 28, 146-155	1.9	0
68	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022 , 129, 336-344	3.7	3
67	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. <i>Journal of Medical Economics</i> , 2022 , 25, 1-7	2.4	1
66	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>BMJ, The</i> , 2022 , 376, e067975	5.9	8
65	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. <i>Pharmacoeconomics</i> , 2022 , 1	4.4	1
64	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force.. <i>Value in Health</i> , 2022 , 25, 10-34	3.3	35

63	Delivering precision oncology to patients with cancer.. <i>Nature Medicine</i> , 2022 , 28, 658-665	50.5	7
62	Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force. <i>Value in Health</i> , 2022 , 25, 869-886	3.3	0
61	Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. <i>European Journal of Health Economics</i> , 2021 , 22, 723-733	3.6	2
60	Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT). <i>Pharmacoeconomics</i> , 2021 , 39, 1075-1084	4.4	
59	Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients.. <i>Current Oncology</i> , 2021 , 28, 5278-5294	2.8	1
58	Gross profits of Canadian pharmacies: A changing policy regime. <i>Healthcare Management Forum</i> , 2020 , 33, 228-232	1.7	
57	Reporting guidelines of health research studies are frequently used inappropriately. <i>Journal of Clinical Epidemiology</i> , 2020 , 122, 87-94	5.7	32
56	Matching-adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics. <i>Clinical and Experimental Allergy</i> , 2020 , 50, 442-452	4.1	13
55	Value assessment of oncology drugs using a weighted criterion-based approach. <i>Cancer</i> , 2020 , 126, 15306-15407	15.4	7
54	Systematic Review of Economic Evaluations of Services Provided by Community Pharmacists. <i>Applied Health Economics and Health Policy</i> , 2020 , 18, 375-392	3.4	
53	Reproducible research practices, openness and transparency in health economic evaluations: study protocol for a cross-sectional comparative analysis. <i>BMJ Open</i> , 2020 , 10, e034463	3	21
52	Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis. <i>PLoS ONE</i> , 2020 , 15, e0240584	3.7	14
51	Citation impact was highly variable for reporting guidelines of health research: a citation analysis. <i>Journal of Clinical Epidemiology</i> , 2020 , 127, 96-104	5.7	7
50	Use of Real-World Data Sources for Canadian Drug Pricing and Reimbursement Decisions: Stakeholder Views and Lessons for Other Countries. <i>International Journal of Technology Assessment in Health Care</i> , 2019 , 35, 181-188	1.8	2
49	Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB). <i>Medical Decision Making</i> , 2019 , 39, 370-378	2.5	9
48	Health Utility Book (HUB)-Cancer: Protocol for a Systematic Literature Review of Health State Utility Values in Cancer. <i>MDM Policy and Practice</i> , 2019 , 4, 2381468319852594	1.5	
47	Variability in aneurysm sac regression after endovascular aneurysm repair based on a comprehensive registry of patients in Eastern Ontario. <i>Journal of Vascular Surgery</i> , 2019 , 70, 1469-1478	3.5	9
46	Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. <i>Value in Health</i> , 2019 , 22, 13-20	3.3	45

45	Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching. <i>Applied Health Economics and Health Policy</i> , 2018 , 16, 279-288	3.4	4
44	Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data. <i>Allergy, Asthma and Clinical Immunology</i> , 2018 , 14, 15	3.2	11
43	Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment. <i>Pharmacoeconomics</i> , 2018 , 36, 7-15	4.4	6
42	Economic evaluations of eHealth technologies: A systematic review. <i>PLoS ONE</i> , 2018 , 13, e0198112	3.7	33
41	Matching-adjusted indirect comparison of benralizumab interleukin-5 inhibitors for the treatment of severe asthma: a systematic review. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	49
40	Guidelines for reporting health economic evaluation studies. <i>Epidemiologia E Servicos De Saude: Revista Do Sistema Unico De Saude Do Brasil</i> , 2017 , 26, 895-898	1.2	2
39	Using Phase-Based Costing of Real-World Data to Inform Decision-Analytic Models for Atrial Fibrillation. <i>Applied Health Economics and Health Policy</i> , 2016 , 14, 313-22	3.4	3
38	Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation. <i>Clinical Pharmacology: Advances and Applications</i> , 2016 , 8, 93-107	1.5	23
37	CHANGING HEALTH TECHNOLOGY ASSESSMENT PARADIGMS?. <i>International Journal of Technology Assessment in Health Care</i> , 2016 , 32, 191-199	1.8	27
36	How do we value a cure?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015 , 15, 551-5	2.2	8
35	Reply to Roberts et al.: CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration. <i>Pharmacoeconomics</i> , 2015 , 33, 535-6	4.4	6
34	How do economic evaluations inform health policy decisions for treatment and prevention in Canada and the United States?. <i>Applied Health Economics and Health Policy</i> , 2015 , 13, 273-9	3.4	9
33	MEDICAL DEVICE PRICES IN ECONOMIC EVALUATIONS. <i>International Journal of Technology Assessment in Health Care</i> , 2015 , 31, 86-9	1.8	3
32	A questionnaire to assess the relevance and credibility of observational studies to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. <i>Value in Health</i> , 2014 , 17, 143-56	3.3	77
31	A synthesis of drug reimbursement decision-making processes in organisation for economic co-operation and development countries. <i>Value in Health</i> , 2014 , 17, 98-108	3.3	40
30	A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and development. <i>PLoS ONE</i> , 2014 , 9, e90434	3.7	22
29	Incorporating economic evaluation into immunization decision making in Canada: a workshop. <i>Expert Review of Vaccines</i> , 2014 , 13, 1291-6	5.2	4
28	Evolution of drug reimbursement in Canada: the Pan-Canadian Pharmaceutical Alliance for new drugs. <i>Value in Health</i> , 2014 , 17, 888-94	3.3	14

27	Health technology assessment and personalized medicine: are economic evaluation guidelines sufficient to support decision making?. <i>International Journal of Technology Assessment in Health Care</i> , 2014 , 30, 179-87	1.8	21
26	Adaptive approaches to licensing, health technology assessment, and introduction of drugs and devices. <i>International Journal of Technology Assessment in Health Care</i> , 2014 , 30, 241-9	1.8	14
25	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>Cost Effectiveness and Resource Allocation</i> , 2013 , 11, 6	2.4	230
24	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>BMC Medicine</i> , 2013 , 11, 80	11.4	151
23	Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. <i>Value in Health</i> , 2013 , 16, 231-50	3.3	1264
22	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>Pharmacoeconomics</i> , 2013 , 31, 361-7	4.4	90
21	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>Value in Health</i> , 2013 , 16, e1-5	3.3	381
20	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>Clinical Therapeutics</i> , 2013 , 35, 356-63	3.5	14
19	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>European Journal of Health Economics</i> , 2013 , 14, 367-72	3.6	136
18	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2013 , 120, 765-70	3.7	25
17	Identifying strategies to improve diabetes care in Alberta, Canada, using the knowledge-to-action cycle. <i>CMAJ Open</i> , 2013 , 1, E142-50	2.5	6
16	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>International Journal of Technology Assessment in Health Care</i> , 2013 , 29, 117-22	1.8	191
15	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>BMJ, The</i> , 2013 , 346, f1049	5.9	659
14	Trends in the utilization of endovascular therapy for elective and ruptured abdominal aortic aneurysm procedures in Canada. <i>Journal of Vascular Surgery</i> , 2012 , 56, 1518-26, 1526.e1	3.5	14
13	Wait times among patients with symptomatic carotid artery stenosis requiring carotid endarterectomy for stroke prevention. <i>Journal of Vascular Surgery</i> , 2012 , 56, 661-7.e1-2	3.5	17
12	Guidelines for health technologies: specific guidance for oncology products in Canada. <i>Value in Health</i> , 2012 , 15, 580-5	3.3	13
11	The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. <i>International Journal of Technology Assessment in Health Care</i> , 2012 , 28, 138-44	1.8	575
10	Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. <i>Cmaj</i> , 2011 , 183, E1189-202	3.5	84

9	Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk. <i>Cmaj</i> , 2011 , 183, E1180-8	3.5	25
8	Editorial [Sentence First, Verdict Afterwards: Using Value of Information Analysis to Inform Decisions about Pharmacogenomic Test Adoption and Research]. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2010 , 8, 167-170	0.4	4
7	Priority setting for health technology assessment at CADTH. <i>International Journal of Technology Assessment in Health Care</i> , 2010 , 26, 341-7	1.8	40
6	Health technology assessment in Canada. <i>International Journal of Technology Assessment in Health Care</i> , 2009 , 25 Suppl 1, 53-60	1.8	24
5	Health technology assessment: a review of international activity and examples of approaches with computed tomographic colonography. <i>Journal of the American College of Radiology</i> , 2009 , 6, 343-52	3.5	2
4	Priority setting for health technology assessments: a systematic review of current practical approaches. <i>International Journal of Technology Assessment in Health Care</i> , 2007 , 23, 310-5	1.8	90
3	Priority setting for health technology assessments: A systematic review of current practical approaches. <i>International Journal of Technology Assessment in Health Care</i> , 2007 , 23, 519-519	1.8	0
2	Long acting beta2 agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomised controlled trials. <i>BMC Pulmonary Medicine</i> , 2004 , 4, 7	3.5	8
1	A general affinity method to purify peroxidase-tagged antibodies. <i>Journal of Immunological Methods</i> , 2001 , 249, 33-41	2.5	13